peer reviewed / Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease-defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification. This rating was mainly based on a retrospective analysis comprising patients from several large...
peer reviewed / Adoptive cell therapy using Chimeric Antigen Receptor (CAR) T cells has revolutionized cancer immunotherapy for a number of hematologic diseases. However, challenges remain in Chronic Lymphocytic Leukemia (CLL) where durable remission rates are low. Previously, we found that CAR vector-mediated disruption of the epigenetic regulator...
peer reviewed / This international questionnaire survey aimed to explore the current incidence, diagnostic policies, management, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) among healthcare providers involved in the management of these patients. A questionnaire was e-mailed to practitioners with an interest in a...
Acute myeloid leukemia (AML) is the most frequent and lethal leukemia among adults. Chemotherapy (cytarabine (Ara-C)) is the first-line treatment option and leads to high remission rates (75%). However, most patients eventually relapse. Relapse is mediated by persisters (i.e., cells surviving the treatment) that present a vast transcriptomic reprog...
peer reviewed / Despite a high response rate in chimeric antigen receptor (CAR) T cell therapy for acute lymphocytic leukaemia (ALL)1-3, approximately 50% of patients relapse within the first year4-6, representing an urgent question to address in the next stage of cellular immunotherapy. Here, to investigate the molecular determinants of ultralong ...
peer reviewed / Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in achieving durable and potentially curative responses in patients with hematological malignancies. CARs are tailored fusion proteins that direct T cells to a specific antigen on tumor cells thereby eliciting a targeted immune response. The approval of ...
peer reviewed / Autologous chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of lymphoid malignancies, leading to the approval of CD19-CAR T cells for B-cell lymphomas and acute leukaemia, and more recently, B-cell maturation antigen-CAR T cells for multiple myeloma. The long-term follow-up of patients treated in the e...
La recherche entreprise au cours de ma thèse explore divers aspects des réponses du système immunitaire après une allogreffe de cellules souches hématopoïétiques (allo-HSCT), mettant l'accent sur la prévention de la GVHD et l'amélioration de l'effet GvT. Mes projets englobent une variété d'approches novatrices. Dans une démarche translationnelle, m...
Rationnel : savoir identifier les patients atteints de lymphome B diffus à grandes cellules (LBDGC) les plus à risque de rechute et de mauvais pronostic est un véritable enjeu, afin de choisir le traitement le plus adapté à chaque groupe de risque. L’essai de phase III GAINED a récemment validé une stratégie thérapeutique basée sur le résultat des ...
